WHO Conditionally Recommends Remdesivir for Severe COVID-19
September 16, 2022
The World Health Organization (WHO) has conditionally recommended Gilead’s COVID-19 antiviral Remdesivir (Veklury), which was already conditionally recommended for non-severe COVID-19. The recommendation was made on positive results from the organization’s SOLIDARITY, which found that patients had a 13% decrease to relative risk of mortality in severe COVID-19 patients.
According to Emily Kimber , “Also supporting the recommendation were results from the National Institute of Allergy and Infectious Diseases’ double-blind placebo-controlled ACTT-1 trial, which demonstrated a mortality reduction in Veklury-treated patients on low flow oxygen at baseline, compared to placebo.”
To read more, click here.
(Source: PM Live, September 16th, 2022)